

Progress with Matinas BioPharma's MAT2203 for invasive fusarium infection. Clinical response achieved in patients resistant to other antifungals.
You can purchase shares of Matinas BioPharma Hldgs (AMEX:MTNB) through any online brokerage.
Other companies in Matinas BioPharma Hldgs’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
There is no analysis for Matinas BioPharma Hldgs to provide a consensus price target.
The stock price for Matinas BioPharma Hldgs (AMEX: MTNB) is $1.18 last updated November 4, 2026 at 12:20 PM EST.
There are no upcoming dividends for Matinas BioPharma Hldgs.
Matinas BioPharma Hldgs does not have any upcoming earnings scheduled.
There is no upcoming split for Matinas BioPharma Hldgs.
Matinas BioPharma Hldgs is in the Health Care sector and Biotechnology industry. They are listed on the AMEX.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe,...